# Study on the Effectiveness of EGb 761® vs Placebo Used for Cognitive Impairment in Patients With Multiple Sclerosis

> **NCT00276341** · PHASE3 · COMPLETED · sponsor: **Ipsen** · enrollment: 47 (actual)

## Conditions studied

- Multiple Sclerosis, Relapsing-Remitting

## Interventions

- **DRUG:** EGb 761® (Tanakan®)

## Key facts

- **NCT ID:** NCT00276341
- **Lead sponsor:** Ipsen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-08-26
- **Primary completion:** —
- **Final completion:** 2005-12-08
- **Target enrollment:** 47 (ACTUAL)
- **Last updated:** 2024-03-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00276341

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00276341, "Study on the Effectiveness of EGb 761® vs Placebo Used for Cognitive Impairment in Patients With Multiple Sclerosis". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT00276341. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*